SHSE:605116 (China)
Â
Class A
Â¥
20.55
+0.84 (+4.26%)
Aug 7
Business Description
Aurisco Pharmaceutical Co Ltd
ISIN : CNE1000042S4
Share Class Description:
SHSE:605116: Class ATotal Employee Number:
2,026Compare
Compare
Traded in other countries / regions
605116.China Index Membership
SSE Composite Index IPO Date
2020-09-21Description
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | 2.03 | |||||
Interest Coverage | 14.16 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.68 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.7 | |||||
3-Year EBITDA Growth Rate | 29.4 | |||||
3-Year EPS without NRI Growth Rate | 28 | |||||
3-Year Book Growth Rate | 16.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.95 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.03 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.44 | |||||
9-Day RSI | 61.45 | |||||
14-Day RSI | 56.57 | |||||
3-1 Month Momentum % | -14.61 | |||||
6-1 Month Momentum % | -28.43 | |||||
12-1 Month Momentum % | -13.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.22 | |||||
Quick Ratio | 2.84 | |||||
Cash Ratio | 1.91 | |||||
Days Inventory | 324.6 | |||||
Days Sales Outstanding | 86.09 | |||||
Days Payable | 157.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.73 | |||||
Dividend Payout Ratio | 0.3 | |||||
3-Year Dividend Growth Rate | 30.7 | |||||
Forward Dividend Yield % | 1.73 | |||||
5-Year Yield-on-Cost % | 1.64 | |||||
Shareholder Yield % | -1.31 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.96 | |||||
Operating Margin % | 30.02 | |||||
Net Margin % | 23.37 | |||||
EBITDA Margin % | 29.06 | |||||
FCF Margin % | 7.85 | |||||
OCF Margin % | 28.73 | |||||
ROE % | 15.4 | |||||
ROA % | 9.68 | |||||
ROIC % | 16.47 | |||||
3-Year ROIIC % | 20.02 | |||||
ROC (Joel Greenblatt) % | 21.4 | |||||
ROCE % | 13.62 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.41 | |||||
Forward PE Ratio | 17.27 | |||||
PE Ratio without NRI | 21.03 | |||||
Shiller PE Ratio | 35.43 | |||||
Price-to-Owner-Earnings | 72.88 | |||||
PEG Ratio | 0.89 | |||||
PS Ratio | 5 | |||||
PB Ratio | 3.07 | |||||
Price-to-Tangible-Book | 3.26 | |||||
Price-to-Free-Cash-Flow | 64.04 | |||||
Price-to-Operating-Cash-Flow | 17.36 | |||||
EV-to-EBIT | 17.31 | |||||
EV-to-EBITDA | 17.31 | |||||
EV-to-Revenue | 5.03 | |||||
EV-to-FCF | 64.08 | |||||
Price-to-GF-Value | 0.7 | |||||
Price-to-Projected-FCF | 4.35 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.84 | |||||
Price-to-Graham-Number | 1.75 | |||||
| Price-to-Net-Current-Asset-Value | 16.98 | |||||
Earnings Yield (Greenblatt) % | 5.78 | |||||
FCF Yield % | 1.58 | |||||
Forward Rate of Return (Yacktman) % | 19.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aurisco Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,684.746 | ||
| EPS (TTM) (Â¥) | 0.96 | ||
| Beta | 0.3099 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 36.61 | ||
| 14-Day RSI | 56.57 | ||
| 14-Day ATR (Â¥) | 0.800762 | ||
| 20-Day SMA (Â¥) | 19.787 | ||
| 12-1 Month Momentum % | -13.33 | ||
| 52-Week Range (Â¥) | 18.09 - 35.58 | ||
| Shares Outstanding (Mil) | 406.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aurisco Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aurisco Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.340000 Cash Dividend | 2026-06-15 | 20.28 (+2.58%) | ||
| CNY 0.290000 Cash Dividend | 2025-06-20 | 20.70 (-2.08%) |
Show
Entries
Aurisco Pharmaceutical Co Ltd Frequently Asked Questions
What is Aurisco Pharmaceutical Co Ltd(SHSE:605116)'s stock price today?
The current price of SHSE:605116 is ¥20.55. The 52 week high of SHSE:605116 is ¥35.58 and 52 week low is ¥18.09.
When is next earnings date of Aurisco Pharmaceutical Co Ltd(SHSE:605116)?
The next earnings date of Aurisco Pharmaceutical Co Ltd(SHSE:605116) is .
Does Aurisco Pharmaceutical Co Ltd(SHSE:605116) pay dividends? If so, how much?
The Dividend Yield %  of Aurisco Pharmaceutical Co Ltd(SHSE:605116) is 1.73% (As of Today), Highest Dividend Payout Ratio of Aurisco Pharmaceutical Co Ltd(SHSE:605116) was 0.3. The lowest was 0.25. And the median was 0.26. The  Forward Dividend Yield % of Aurisco Pharmaceutical Co Ltd(SHSE:605116) is 1.73%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Aurisco gets Auxiton® (Dydrogesterone) as first generic approval in China | 2023-06-27 |
Articles on Aurisco Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers